Assessing the safety of influenza vaccination in specific populations: Children and the elderly

Expert Review of Vaccines

Volumn 11, Issue 8, 2012, Pages 973-984

  Rowhani Rahbar, Ali ^a   Klein, Nicola P ^a   Baxter, Roger ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

aged; child; influenza; safety; vaccines

Indexed keywords

INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE;

ABDOMINAL PAIN; ANAPHYLAXIS; ASTHMA; COMMON COLD; COUGHING; CYTOKINE PRODUCTION; DECREASED APPETITE; DOSE RESPONSE; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DUODENITIS; DYSPNEA; EFFUSION; FEBRILE CONVULSION; GASTRITIS; GUILLAIN BARRE SYNDROME; HOARSENESS; HUMAN; ICD-9; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INTEGRATED HEALTH CARE SYSTEM; IRRITABILITY; LOWER RESPIRATORY TRACT INFECTION; MALAISE; MUSCULOSKELETAL PAIN; MYALGIA; NARCOLEPSY; NAUSEA; NOSE CONGESTION; OTITIS MEDIA; PRIORITY JOURNAL; REVIEW; RHINORRHEA; SEASONAL INFLUENZA; SIDE EFFECT; SNEEZING; SORE THROAT; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VOMITING; WHEEZING;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ASTHMA; CHILD, PRESCHOOL; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; NARCOLEPSY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEIZURES, FEBRILE; VACCINATION; VACCINES, LIVE, UNATTENUATED;

EID: 84866686308     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.66     Document Type: Review

References (144)

1. van Essen GA, Palache AM, Forleo E, Fedson DS. Influenza vaccination in 2000: recommendations and vaccine use in 50 developed and rapidly developing countries. Vaccine 21(16), 1780-1785 (2003).
2. Fiore AE, Uyeki TM, Broder K et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR. Recomm. Rep. 59(RR-8), 1-62 (2010).
3. Mereckiene J, Cotter S, D'Ancona F et al.; VENICE project gatekeepers group. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. Euro Surveill. 15(44), 1-10 (2010).
4. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N. Engl. J. Med. 342(4), 225-231 (2000).
5. Principi N, Esposito S, Marchisio P, Gasparini R, Crovari P. Socioeconomic impact of influenza on healthy children and their families. Pediatr. Infect. Dis. J. 22(Suppl. 10), S207-S210 (2003).
6. Greene SK, Kulldorff M, Lewis EM et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am. J. Epidemiol. 171(2), 177-188 (2010).
7. Lee GM, Greene SK, Weintraub ES et al.; Vaccine Safety Datalink Project. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am. J. Prev. Med. 41(2), 121-128 (2011).
8. Wright PF, Sell SH, Thompson J, Karzon DT. Clinical reactions and serologic response following inactivated monovalent influenza type B vaccine in young children and infants. J. Pediatr. 88(1), 31-35 (1976).
9. Vasil'eva RI, Merkur'eva LA, Iatsenko VG, Vasil'eva AM, Shvager MM. Characteristics of the clinical and immunologic safety of inactivated influenza vaccines in children undergoing multiple immunizations. Zh. Mikrobiol. Epidemiol. Immunobiol. 11, 65-69 (1988).
10. Beutner KR, Chow T, Rubi E, Strussenberg J, Clement J, Ogra PL. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J. Infect. Dis. 140(6), 844-850 (1979).
11. Gruber WC, Taber LH, Glezen WP et al. Live attenuated and inactivated influenza vaccine in school-age children. Am. J. Dis. Child. 144(5), 595-600 (1990).
12. Gutman LT, Wilfert CM, Idriss ZH, Schmidt E, Andrews S, Katz SL. Singledose trials of monovalent A/New Jersey/76 (Hsw1N1) influenza virus vaccine in children in Durham, North Carolina. J. Infect. Dis. 136, S575-S578 (1977).
13. Slepushkin AN, Obrosova-Serova NP, Burtseva EI et al. A comparative study of the inoculation properties of live recombinant and inactivated influenza vaccines made from strain A/Philippines/2/82 (H3N2) in 8-to 15-year-old children. Vopr. Virusol. 36(5), 372-374 (1991).
14. Barry DW, Mayner RE, Hochstein HD et al. Comparative trial of influenza vaccines. II. Adverse reactions in children and adults. Am. J. Epidemiol. 104(1), 47-59 (1976).
15. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst. Rev. 2, CD004879 (2008).
16. France EK, Glanz JM, Xu S et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch. Pediatr. Adolesc. Med. 158(11), 1031-1036 (2004).
17. Glanz JM, Newcomer SR, Hambidge SJ et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch. Pediatr. Adolesc. Med. 165(8), 749-755 (2011).
18. Hambidge SJ, Glanz JM, France EK et al.; Vaccine Safety Datalink Team. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 296(16), 1990-1997 (2006).
19. Neuzil KM, Dupont WD, Wright PF, Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience. Pediatr. Infect. Dis. J. 20(8), 733-740 (2001).
20. El'shina GA, Gorbunov MA, Bektimirov TA et al. The evaluation of the reactogenicity, harmlessness and prophylactic efficacy of Grippol trivalent polymer-subunit influenza vaccine administered to schoolchildren. Zh. Mikrobiol. Epidemiol. Immunobiol. (2), 50-54 (2000).
21. Vasil'eva RI, Osidak LV, Bichurina MA, Mukhina LP, Chudina LV. [Evaluation of the safety, reactogenicity and antigenic activity of inactivated chromatographic influenza vaccine in school children]. Zh. Mikrobiol. Epidemiol. Immunobiol. 4, 96-98 (1982).
22. Vasil'eva RI, Smirnova LA, Rudenko LG, Drinevskii VP, Tsaritsina IM. The results of state trials of inactivated influenza vaccines for children. Zh. Mikrobiol. Epidemiol. Immunobiol. 3, 49-54 (1988).
23. Baxter R, Jeanfreau R, Block SL et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr. Infect. Dis. J. 29(10), 924-930 (2010).
24. Nolan T, Richmond PC, McVernon J et al. Safety and immunogenicity of an inactivated thimerosal-free influenza vaccine in infants and children. Influenza Other Respi. Viruses 3(6), 315-325 (2009).
25. Bohlke K, Davis RL, Marcy SM et al.; Vaccine Safety Datalink Team. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics 112(4), 815-820 (2003).
26. Kelso JM. Administration of influenza vaccines to patients with egg allergy: update for the 2010-2011 season. J. Allergy Clin. Immunol. 126(6), 1302-1304 (2010).
27. Kelso JM. Administration of influenza vaccines to patients with egg allergy. J. Allergy Clin. Immunol. 125(4), 800-802 (2010).
28. Kelso JM, Li JT, Nicklas RA et al.; Joint Task Force on Practice Parameters; Joint Task Forcce on Practice Parameters for Allergy & Immunology. Adverse reactions to vaccines. Ann. Allergy Asthma Immunol. 103(4 Suppl. 2), S1-S14 (2009).
29. Kelso JM. Update on vaccination guidelines for allergic children. Expert Rev. Vaccines 8(11), 1541-1546 (2009).
30. Centers for Disease Control and Prevention. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb. Mortal Wkly. Rep. 60(33), 1128-1132 (2011).
31. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2011-2012. Pediatrics 128(4), 813-825 (2011).
32. Wood RA, Berger M, Dreskin SC et al.; Hypersensitivity Working Group of the Clinical Immunization Safety Assessment (CISA) Network. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics 122(3), e771-e777 (2008).
33. Armstrong PK, Dowse GK, Effler PV et al. Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine. BMJ Open 1(1), e000016 (2011).
34. Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine 27(32), 4278-4283 (2009).
35. McMahon AW, Iskander J, Haber P et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics 115(2), 453-460 (2005).
36. Wood N, Sheppeard V, Cashman P et al. Influenza vaccine safety in children less than 5 years old: the 2010 and 2011 experience in Australia. Pediatr. Infect. Dis. J. 31(2), 199-202 (2012).
37. Blyth CC, Currie AJ, Wiertsema SP et al. Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms. Vaccine 29(32), 5107-5113 (2011).
38. Centers for Disease Control and Prevention. Update: recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding use of CSL seasonal influenza vaccine (Afluria) in the United States during 2010-11. MMWR Morb. Mortal Wkly. Rep. 59(31), 989-992 (2010).
39. Varricchio F, Iskander J, Destefano F et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr. Infect. Dis. J. 23(4), 287-294 (2004).
40. Tse A, Tseng HF, Greene SK, Vellozzi C, Lee GM; VSD Rapid Cycle Analysis Influenza Working Group. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 30(11), 2024-2031 (2012).
41. Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7(3), e33536 (2012).
42. Partinen M, Saarenpää-Heikkilä O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7(3), e33723 (2012).
43. Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 26(Suppl. 4), D10-D16 (2008).
44. Belshe RB, Mendelman PM, Treanor J et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338(20), 1405-1412 (1998).
45. Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J. 23(2), 138-144 (2004).
46. Gaglani MJ, Piedra PA, Riggs M, Herschler G, Fewlass C, Glezen WP. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr. Infect. Dis. J. 27(5), 444-452 (2008).
47. King JC Jr, Lagos R, Bernstein DI et al. Safety and immunogenicity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect. Dis. 177(5), 1394-1397 (1998).
48. Nolan T, Lee MS, Cordova JM et al. Safety and immunogenicity of a live-attenuated influenza vaccine blended and filled at two manufacturing facilities. Vaccine 21(11-12), 1224-1231 (2003).
49. Piedra PA, Gaglani MJ, Riggs M et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 116(3), e397-e407 (2005).
50. Piedra PA, Yan L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110(4), 662-672 (2002).
51. Redding G, Walker RE, Hessel C et al. Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr. Infect. Dis. J. 21(1), 44-48 (2002).
52. Zangwill KM, Droge J, Mendelman P et al. Prospective, randomized, placebocontrolled evaluation of the safety and immunogenicity of three lots of intranasal trivalent influenza vaccine among young children. Pediatr. Infect. Dis. J. 20(8), 740-746 (2001).
53. Belshe RB, Edwards KM, Vesikari T et al.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356(7), 685-696 (2007).
54. Vesikari T, Fleming DM, Aristegui JF et al.; CAIV-T Pediatric Day Care Clinical Trial Network. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against communityacquired, culture-confirmed influenza in young children attending day care. Pediatrics 118(6), 2298-2312 (2006).
55. Alexandrova GI, Budilovsky GN, Koval TA et al. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine 4(2), 114-118 (1986).
56. Desheva IUA, Danini GV, Grigor'eva EP et al. The investigation of the safety, genetic stability and immunogenicity of live influenza vaccine for adults in vaccination of 3-6 years old children. Vopr. Virusol. 47(4), 21-24 (2002).
57. Grigor'eva EP, Rekstin AR, Rudenko LG et al. The immunogenic properties and prophylactic efficacy of a live polyvalent influenza vaccine in children 5 to 14 years old. Vopr. Virusol. 39(1), 26-29 (1994).
58. Khan AS, Polezhaev F, Vasiljeva R et al. Comparison of US inactivated split-virus and Russian live attenuated, cold-adapted trivalent influenza vaccines in Russian schoolchildren. J. Infect. Dis. 173(2), 453-456 (1996).
59. Rudenko LG, Ramirez A, Barro M et al. The inoculation properties of live recombinant influenza vaccine types A and B used separately and jointly in children 3 to 14. Vopr. Virusol. 36(6), 472-474 (1991).
60. Rudenko LG, Vasil'eva RI, Ismagulov AT et al. Prophylactic effectiveness of a live recombinant influenza type A vaccine in immunizing children aged 3-14 years. Vopr. Virusol. 41(1), 37-39 (1996).
61. Slepushkin AN, Dukova VS, Kalegaeva VA, Kagan AN, Temriuk EE. Results of studying the effectiveness of a live influenza vaccine for peroral use on preschool and schoolchildren. Zh. Mikrobiol. Epidemiol. Immunobiol. 12, 24-29 (1974).
62. Swierkosz EM, Newman FK, Anderson EL, Nugent SL, Mills GB, Belshe RB. Multidose, live attenuated, coldrecombinant, trivalent influenza vaccine in infants and young children. J. Infect. Dis. 169(5), 1121-1124 (1994).
63. Gruber WC, Belshe RB, King JC et al. Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza Vaccine Investigators Group. J. Infect. Dis. 173(6), 1313-1319 (1996).
64. Belshe RB. The need for quadrivalent vaccine against seasonal influenza. Vaccine 28(Suppl. 4), D45-D53 (2010).
65. Lum LC, Borja-Tabora CF, Breiman RF et al. Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children. Vaccine 28(6), 1566-1574 (2010).
66. Nolan T, Bernstein DI, Block SL et al.; LAIV Study Group. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 121(3), 508-516 (2008).
67. Baxter R, Toback SL, Sifakis F et al. A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18-49 years of age. Vaccine 30(20), 3053-3060 (2012).
68. Govaert TM, Dinant GJ, Aretz K, Masurel N, Sprenger MJ, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 307(6910), 988-990 (1993).
69. Keitel WA, Cate TR, Atmar RL et al. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin. Diagn. Lab. Immunol. 3(5), 507-510 (1996).
70. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly. A randomized, placebo-controlled trial. JAMA 264(9), 1139-1141 (1990).
71. Treanor J, Dumyati G, O'Brien D et al. Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults. J. Infect. Dis. 169(2), 402-407 (1994).
72. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst. Rev. 7, CD001269 (2010).
73. Couch RB, Winokur P, Brady R et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25(44), 7656-7663 (2007).
74. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis. 200(2), 172-180 (2009).
75. Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med. 166(10), 1121-1127 (2006).
76. Schwarz TF, Flamaing J, Rümke HC et al. A randomized, double-blind trial to evaluate immunogenicity and safety of 13-valent pneumococcal conjugate vaccine given concomitantly with trivalent influenza vaccine in adults aged ≥65 years. Vaccine 29(32), 5195-5202 (2011).
77. Weston WM, Chandrashekar V, Friedland LR, Howe B. Safety and immunogenicity of a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine when co-administered with influenza vaccine in adults. Hum. Vaccin. 5(12), 858-866 (2009).
78. Kerzner B, Murray AV, Cheng E et al. Safety and immunogenicity profile of the concomitant administration of ZOSTAVAX and inactivated influenza vaccine in adults aged 50 and older. J. Am. Geriatr. Soc. 55(10), 1499-1507 (2007).
79. McNeil SA, Noya F, Dionne M et al. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults. Vaccine 25(17), 3464-3474 (2007).
80. Sejvar JJ, Kohl KS, Gidudu J et al.; Brighton Collaboration GBS Working Group. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29(3), 599-612 (2011).
81. Ropper AH. The Guillain-Barré syndrome. N. Engl. J. Med. 326(17), 1130-1136 (1992).
82. Guarino M, Casmiro M, D'Alessandro R. Campylobacter jejuni infection and Guillain-Barré syndrome: a case-control study. Emilia-Romagna Study Group on Clinical and Epidemiological problems in neurology. Neuroepidemiology 17(6), 296-302 (1998).
83. Jacobs BC, Rothbarth PH, van der Meché FG et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 51(4), 1110-1115 (1998).
84. Sheikh KA, Nachamkin I, Ho TW et al. Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndrome: molecular mimicry and host susceptibility. Neurology 51(2), 371-378 (1998).
85. Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 125(Pt 12), 2591-2625 (2002).
86. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ et al. Guillain-Barré syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am. J. Epidemiol. 110(2), 105-123 (1979).
87. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N. Engl. J. Med. 304(26), 1557-1561 (1981).
88. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. Lack of an association with influenza vaccination. JAMA 248(6), 698-700 (1982).
89. Burwen DR, Ball R, Bryan WW et al. Evaluation of Guillain-Barré Syndrome among recipients of influenza vaccine in 2000. and 2001. Am. J. Prev. Med. 39(4), 296-304 (2010).
90. Hughes RA, Charlton J, Latinovic R, Gulliford MC. No association between immunization and Guillain-Barré syndrome in the United Kingdom, 1992 to 2000. Arch. Intern. Med. 166(12), 1301-1304 (2006).
91. Roscelli JD, Bass JW, Pang L. Guillain-Barré syndrome and influenza vaccination in the US Army, 1980-1988. Am. J. Epidemiol. 133(9), 952-955 (1991).
92. Stowe J, Andrews N, Wise L, Miller E. Investigation of the temporal association of Guillain-Barré syndrome with influenza vaccine and influenzalike illness using the United Kingdom General Practice Research Database. Am. J. Epidemiol. 169(3), 382-388 (2009).
93. Tam CC, O'Brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. Guillain-Barré syndrome and preceding infection with campylobacter, influenza and Epstein-Barr virus in the general practice research database. PLoS ONE 2(4), e344 (2007).
94. Lasky T, Terracciano GJ, Magder L et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N. Engl. J. Med. 339(25), 1797-1802 (1998).
95. Juurlink DN, Stukel TA, Kwong J et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch. Intern. Med. 166(20), 2217-2221 (2006).
96. Baxter R, Lewis N, Bakshi N, Vellozzi C, Klein NP; CISA Network. Recurrent Guillain-Barré syndrome following vaccination. Clin. Infect. Dis. 54(6), 800-804 (2012).
97. Moro PL, Broder K, Zheteyeva Y et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009. monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am. J. Obstet. Gynecol. 205(5), 473.e1-473.e9 (2011).
98. Salmon DA, Akhtar A, Mergler MJ et al.; H1N1 Working Group of Federal Immunization Safety Task Force. Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program. Pediatrics 127(Suppl. 1), S78-S86 (2011).
99. Williams SE, Pahud BA, Vellozzi C et al. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine 29(46), 8302-8308 (2011).
100. Andrews N, Stowe J, Al-Shahi Salman R, Miller E. Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: selfcontrolled case series. Vaccine 29(45), 7878-7882 (2011).
101. Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M; VAESCO-GBS Case-Control Study Group. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009. vaccine: multinational case-control study in Europe. BMJ 343, d3908 (2011).
102. Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine-United States, 2009-2010. MMWR Morb. Mortal Wkly. Rep. 59(21), 657-661 (2010).
103. Greene SK, Rett M, Weintraub ES et al. Risk of confirmed Guillain-Barré syndrome following receipt of monovalent inactivated influenza A (H1N1) and seasonal influenza vaccines in the Vaccine Safety Datalink Project, 2009-2010. Am. J. Epidemiol. 175(11), 1100-1109 (2012).
104. Wise ME, Viray M, Sejvar JJ et al. Guillain-Barré syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million Americans. Am. J. Epidemiol. 175(11), 1110-1119 (2012).
105. IOM (Institute of Medicine). Adverse Effects of Vaccines: Evidence and Causality. The National Academic Press, Washington, DC, USA (2011).
106. Jackson LA, Holmes SJ, Mendelman PM, Huggins L, Cho I, Rhorer J. Safety of a trivalent live attenuated intranasal influenza vaccine, FluMist, administered in addition to parenteral trivalent inactivated influenza vaccine to seniors with chronic medical conditions. Vaccine 17(15-16), 1905-1909 (1999).
107. Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med. 117(8), 625-633 (1992).
108. Dormitzer PR, Tsai TF, Del Giudice G. New technologies for influenza vaccines. Hum. Vaccin. Immunother. 8(1), 45-58 (2012).
109. Halperin SA, Nestruck AC, Eastwood BJ. Safety and immunogenicity of a new influenza vaccine grown in mammalian cell culture. Vaccine 16(13), 1331-1335 (1998).
110. Groth N, Montomoli E, Gentile C, Manini I, Bugarini R, Podda A. Safety, tolerability and immunogenicity of a mammalian cell-culture-derived influenza vaccine: a sequential Phase I and Phase II clinical trial. Vaccine 27(5), 786-791 (2009).
111. Palache AM, Brands R, van Scharrenburg GJ. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J. Infect. Dis. 176(Suppl. 1), S20-S23 (1997).
112. Palache AM, Scheepers HS, de Regt V et al. Safety, reactogenicity and immunogenicity of Madin Darby Canine Kidney cell-derived inactivated influenza subunit vaccine. A meta-analysis of clinical studies. Dev. Biol. Stand. 98, 115-25; discussion 133 (1999).
113. Halperin SA, Smith B, Mabrouk T et al. Safety and immunogenicity of a trivalent, inactivated, mammalian cell culturederived influenza vaccine in healthy adults, seniors, and children. Vaccine 20(7-8), 1240-1247 (2002).
114. Reisinger KS, Block SL, Izu A, Groth N, Holmes SJ. Subunit influenza vaccines produced from cell culture or in embryonated chicken eggs: comparison of safety, reactogenicity, and immunogenicity. J. Infect. Dis. 200(6), 849-857 (2009).
115. Ehrlich HJ, Müller M, Oh HM et al.; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med. 358(24), 2573-2584 (2008).
116. Keitel W, Groth N, Lattanzi M et al. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a Phase 1/2 clinical trial. Vaccine 28(3), 840-848 (2010).
117. Szymczakiewicz-Multanowska A, Groth N, Bugarini R et al. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture. J. Infect. Dis. 200(6), 841-848 (2009).
118. Taylor DN, Treanor JJ, Strout C et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 29(31), 4897-4902 (2011).
119. López-Macías C, Ferat-Osorio E, Tenorio-Calvo A et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine 29(44), 7826-7834 (2011).
120. Landry N, Ward BJ, Trépanier S et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS ONE 5(12), e15559 (2010).
121. Ansaldi F, de Florentiis D, Durando P, Icardi G. Fluzone® Intradermal vaccine: a promising new chance to increase the acceptability of influenza vaccination in adults. Expert Rev. Vaccines 11(1), 17-25 (2012).
122. Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650-658 (2008).
123. Van Damme P, Arnou R, Kafeja F et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect. Dis. 10, 134 (2010).
124. Icardi G, Orsi A, Ceravolo A, Ansaldi F. Current evidence on intradermal influenza vaccines administered by Soluvia™ licensed micro injection system. Hum. Vaccin. Immunother. 8(1), 67-75 (2012).
125. Gelinck LB, van den Bemt BJ, Marijt WA et al. Intradermal influenza vaccination in immunocompromized patients is immunogenic and feasible. Vaccine 27(18), 2469-2474 (2009).
126. Lewis DJ, Huo Z, Barnett S et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 4(9), e6999 (2009).
127. Mutsch M, Zhou W, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350(9), 896-903 (2004).
128. Amorij JP, Hinrichs WLj, Frijlink HW, Wilschut JC, Huckriede A. Needle-free influenza vaccination. Lancet Infect. Dis. 10(10), 699-711 (2010).
129. Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum. Vaccin. Immunother. 8(1), 81-88 (2012).
130. Principi N, Esposito S. Adjuvanted influenza vaccines. Hum. Vaccin. Immunother. 8(1), 59-66 (2012).
131. O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines 6(5), 699-710 (2007).
132. Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin. Biol. Ther. 10(4), 639-651 (2010).
133. Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 26(26), 3209-3222 (2008).
134. Vesikari T, Pellegrini M, Karvonen A et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr. Infect. Dis. J. 28(7), 563-571 (2009).
135. Vesikari T, Knuf M, Wutzler P et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365(15), 1406-1416 (2011).
136. Nicholson KG, Abrams KR, Batham S et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03Aadjuvanted 2009. influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect. Dis. 11(2), 91-101 (2011).
137. Meier S, Bel M, L'huillier A et al.; H1N1 Epidemiology Study Group of Geneva. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 29(19), 3548-3557 (2011).
138. Rahier JF, Papay P, Salleron J et al.; European Crohn's and Colitis Organisation (ECCO). H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 60(4), 456-462 (2011).
139. Neuzil KM, Englund JA. Influenza vaccine for young children: two doses are better than one. J. Pediatr. 149(6), 737-738 (2006).
140. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6-to 23-month-old children. Pediatrics 115(4), 1039-1047 (2005).
141. Baxter R, Ray GT, Fireman BH. Effect of influenza vaccination on hospitalizations in persons aged 50 years and older. Vaccine 28(45), 7267-7272 (2010).
142. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12(1), 36-44 (2012).
143. Fireman B, Lee J, Lewis N, Bembom O, van der Laan M, Baxter R. Influenza vaccination and mortality: differentiating vaccine effects from bias. Am. J. Epidemiol. 170(5), 650-656 (2009).
144. Baxter R, Patriarca PA, Ensor K, Izikson R, Goldenthal KL, Cox MM. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 29(12), 2272-2278 (2011).